Clinical trials: Prostate Carcinoma, open to volunteers
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of…
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05946213
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 436 sites in United States, Canada and 3 more
- Volunteers
- 1,500 people
- Sponsor
- NRG Oncology
Prostate Cancer, Leukemia
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Study Description: ELEA is an observational cohort study that will collect exposure information and biospecimens from the adult children of the Agricultural Health Study (AHS) cohort (https://aghealth.nih.gov/about; Protocol…
- Conditions
- Prostate Cancer, Leukemia, Breast Cancer, Melanoma
- Trial name
- NCT07328516
- Where
- United States
- Volunteers
- 64,277 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Exercise-induced Steroid Changes in Active Surveillance for Prostate Cancer
The purpose of this research study is to understand how a short session of a home-based bodyweight high-intensity interval training (HIIT) affects steroid hormone levels in men on active surveillance for low-grade prostate cancer.
- Trial name
- ESCAPE (NCT07518888)
- Testing
- High-Intensity Interval Training (HIIT) Exercise
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care…
- Trial name
- NCT07570979
- Testing
- INR731, Enzalutamide, Abiraterone
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma, Prostate Cancer
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring.
- Conditions
- Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma
- Trial name
- NCT07574541
- Testing
- TriAdeno vaccine, N-803
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
Prostate cancer is the most common cancer in Australian men. Robot-assisted radical prostatectomy (RARP) - surgical removal of the prostate - is a standard treatment, but it frequently causes erectile dysfunction (ED) and urinary…
- Conditions
- Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer, Urinary Incontinence Following Surgical Procedure
- Trial name
- ROBOPREP (NCT07576335)
- Testing
- Tadalafil 5 mg, Pelvic Floor Muscle Training (PFMT), Aerobic Exercise Program
- Where
- 3 sites in Australia
- Volunteers
- 64 people
- Sponsor
- Surgical Outcomes Research Centre (SOuRCe)
Metastatic Castration-resistant Prostate Cancer
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic…
- Trial name
- NCT07609225
- Testing
- 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
Prostate Cancer
Hong Kong Prostate Cancer Study Group Database
Prostate cancer (PCa) is ranked 3rd in annual incidence of male cancer and ranked 5th for cancer-related death in men in Hong Kong which accounts for about 9.1 deaths per 100,000 men in 2011.
- Trial name
- NCT03344835
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 15,000 people
- Sponsor
- Chinese University of Hong Kong
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 581 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population
Prostate cancer (PC) is highly prevalent worldwide and is currently the 3rd most commonly diagnosed prostate cancer in Hong Kong male population with more than 1600 new cases diagnosed per year.
- Trial name
- NCT03893929
- Testing
- New Biological markers for prostate cancer diagnosis and management
- Where
- Hong Kong
- Volunteers
- 5,000 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
To Identify Potential New Urine Markers for the Screening of Prostate Cancer
Prostate gland is a clinically important male sexual organ and its main function is for the production of semen. Globally, it is the second most common cancer in men globally and is also the fifth cancer cause for death in male.
- Trial name
- NCT03914391
- Where
- Hong Kong
- Volunteers
- 10,000 people
- Sponsor
- Chinese University of Hong Kong
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04489719
- Testing
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
This clinical trial evaluates whether having a trained peer navigator helps African American men with prostate cancer that has spread to other parts of the body (metastatic) understand and navigate the genetic testing process…
- Conditions
- Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT05487846
- Testing
- Patient Navigation, Genetic Counseling, Survey Administration
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Thomas Jefferson University
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Trial name
- CONCORD (NCT07052578)
- Where
- 28 sites in Russia
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Prostate Cancer
The Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
This study is to assess the effect of Pulsed electromagnetic fields (PEMF) on improving muscle mass and strength in prostate cancer patients with ADT.
- Trial name
- NCT07057375
- Testing
- Pulsed electromagnetic fields Thearpy
- Where
- Hong Kong
- Volunteers
- 110 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Prostate Cancer
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
- Trial name
- SEACLIFF (NCT07181161)
- Testing
- AZD0516, AZD9574
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Hypogonadism, Prostate Cancer
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in…
- Trial name
- REVIVE (NCT07535905)
- Testing
- Tamoxifen
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University Health Network, Toronto